22 results about "Anemia" patented technology

The invention relates to a weight loss intervention method and device for chronic renal failure and obesity patients based on an individualized prescription. The method comprises the following steps: constructing a multi-modal dynamic time sequence feature vector of a patient; identifying and quantifying potential causal effects of different weight loss intervention measures on physiological outcomes of renal functions, electrolyte balance, anemia states, bone mineral metabolism and weight indexes of the CKD patient according to a dual robust estimator; dynamically constructing a weight loss intervention measure causal model according to the potential causal effect of the physiological outcome of each patient and the physiological and pathological background; and inputting the multi-modal dynamic time sequence feature vector of the patient into a weight loss intervention measure causal model, and generating a daily diet scheme, an exercise scheme and corresponding high-confidence risk early warning and causal explanation of the patient. The method overcomes the limitation that the traditional method only pays attention to correlation and cannot clearly determine the intervention effect, ensures that the causal atlas and the intervention scheme are optimized according to the real-time change state of the patient, and realizes a real dynamic prescription.

The present invention relates to the technical field of biology, and specifically relates to a primer set and the use thereof in the preparation of a thalassemia detection kit. The primer set comprises primers designed on the basis of at least one of sequences 1)-13): 1) chr16:219267-219290; 2) chr16:228804-228829; 3) chr16:215255-215276; 4) chr16:235945-235971; 5) chr16:196488-196508; 6) chr11:5276986-5277008; 7) chr11:5257290-5257314; 8) chr11:5249915-5249939; 9) chr11:5258978-5259000; 10) chr11:5221888-5221912; 11) chr11:5189975-5189996; 12) chr11:5152341-5152365; 13) chr11:5133905-5133925, wherein the primers are at least partially complementary to sequences 1)-13).

The application discloses a kind of dabigatran bleeding risk prediction methods based on machine learning, it is related to computer-aided drug risk management technical field, the method is by obtaining patient baseline and follow-up data, multiple imputation method is handled missing value;With HAS-BLED score as the basis, candidate variables are screened from potential risk factors using LassoCV algorithm, and anemia, insulin use and antifungal agent use are determined as new prediction variables through clinical correlation analysis to construct a set of prediction variables;Finally, a random forest or gradient boosting algorithm is used to train the model to output the bleeding risk assessment results of the individual to be tested.The application combines machine learning algorithm, improves the prediction accuracy of dabigatran bleeding risk in Chinese non-valvular atrial fibrillation patients, solves the problem of insufficient prediction accuracy of traditional HAS-BLED score, and provides a more reliable basis for clinical individualized anticoagulant therapy decision.

The present application relates to the technical field of glycated hemoglobin detection, and particularly relates to a glycated hemoglobin chromatographic detection method for pregnancy risk assessment, comprising the following steps: obtaining serum ferritin concentration, glycated hemoglobin concentration and C-reactive protein concentration of pregnant women; analyzing reference value weight of each pregnant woman according to distribution of serum ferritin concentration and C-reactive protein concentration of each pregnant woman and body mass index of each pregnant woman, and then obtaining data correction coefficient; obtaining serum ferritin reference value according to serum ferritin concentration, C-reactive protein concentration and glycated hemoglobin concentration of pregnant women; adjusting glycated hemoglobin concentration of a target pregnant woman according to data correction coefficient, serum ferritin reference value and serum ferritin concentration of the target pregnant woman, and then obtaining glycated hemoglobin detection result of the target pregnant woman. The present application can eliminate interference caused by iron deficiency or anemia, and make glycated hemoglobin detection result more accurate.

The present application relates to the technical field of platelet aggregation detection, and specifically discloses a clinical platelet aggregation detection carrier, which comprises an instrument body and further comprises: a detection assembly arranged inside the instrument body, which is used for detecting different types of samples of lipemia, anemia and normal blood and selecting centrifugal operation of the blood samples; the detection assembly can detect different types of samples of lipemia, anemia and normal blood, and can automatically indicate whether centrifugal operation of the blood is needed according to the types of the detected samples; through the sampling assembly, the blood samples at different layer depths can be automatically adjusted according to the lipemia, anemia and normal blood samples detected by the detection assembly; through the agent adding assembly, the amount of the added inducing agent can be automatically adjusted according to the sample amount taken by the sampling assembly, so that the concentration of the mixed inducing agent reaches the specified range, thereby improving the detection accuracy of the platelet aggregation degree.

The invention belongs to the technical field of medical ultrasonic remote monitoring, and discloses an echocardiogram remote monitoring system for a heart failure patient, which can capture acute cardiac function deterioration corresponding to paroxysmal dyspnea and postural chest distress at night in real time through a symptom pre-recognition module, an emergency level data transmission mechanism and continuous cardiac function parameter calculation; the system no longer only transmits static images, but generates a continuous cardiac function dynamic curve, and combines a causal reasoning algorithm to help doctors to clearly distinguish physiological and pathological attributes of parameter fluctuation, so that intervention delay caused by monitoring lag is avoided, a precious treatment window is won for acute cardiac function deterioration, and the risk of acute exacerbation of heart failure is reduced; based on the integrated data, the causal reasoning algorithm can quickly locate the heart failure deterioration pathogenesis, such as association between EF value decrease and anemia and renal injury, a physician does not need to manually integrate data across platforms, the time consumed for pathogenesis investigation is reduced, timely adjustment of a treatment scheme is ensured, and blind medication caused by unknown pathogenesis is avoided.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension. 20 24 20 43 42 25 J un 2 02 4 A B S T R A C T 2 0 2 4 2 0 4 3 4 2 2 5 J u n 2 0 2 4

The application relates to a non-invasive anemia classification method based on a palpebral conjunctival image, which comprises the following steps: improving an SE attention module, performing channel dimension compression and importance weighting on an input feature map through the fusion of adaptive average pooling and adaptive maximum pooling to obtain a DPFSE module; using resnext50 as a main architecture, introducing the DPFSE module on the basis of a residual block to obtain a DPFSE-ResBlock module; introducing an SE module before the first residual block to obtain a final Dual-DPFSE-ResNext50 network model; and using the constructed Dual-DPFSE-ResNext50 anemia analysis model to classify palpebral conjunctival images through the anemia analysis model to obtain an anemia classification result. The application fuses the DPFSE module and the residual module to form a double-pooling fusion SE residual module, introduces the attention module at the beginning, forms a deeper module, and thus makes a new breakthrough in the classification ability of the constructed anemia analysis model, and improves the non-invasive anemia classification accuracy.

This invention provides a multi-functional vein visualization device and blood collection site management system that simplifies and reduces the cost of the device configuration while simultaneously performing screening for biological risks such as dehydration and anemia. [Solution] The system comprises a single imaging unit 22 that does not have a spectral filter on the light receiving path that receives reflected light from the target area, a light source unit 21 that sequentially switches and time-division irradiates the target area with four specific wavelengths of light: 660nm, 760nm, 850nm, and 940nm, an information processing unit 23 that extracts the spatial position of the veins in the target area and calculates an estimated index of the internal biological state from the absorbance at the target pixel based on the reflected images of each of the four specific wavelengths of light acquired by the imaging unit 22 in synchronization with the time-division irradiation by the light source unit 21, and an output unit 24 that outputs the spatial position of the veins and the estimated index extracted by the information processing unit 23.

The invention belongs to the technical field of biological medicines, and particularly relates to a pharmaceutical composition for treating thalassemia and application thereof. The invention provides a pharmaceutical composition for treating thalassemia, which comprises: (a) a cell population containing a first type of cells and a second type of cells, the cell population can be used for differentiating to generate red blood cells, target loci of the first type of cells are edited to increase red blood cells expressing functional hemoglobin generated by differentiation of the cell population, and target loci of the second type of cells are edited to generate target loci of the second type of cells; the target gene loci of the second type of cells are not edited; (b) a mobilizing agent. The medicine composition can achieve the effect of treating thalassemia through cell transplantation without removing marrow, and the clinical treatment risk of a patient is reduced.

The invention provides an anemia risk prediction method and system based on blood drying morphology analysis, and the method comprises the steps: obtaining clinical blood samples with different blood qualities, and carrying out the drying treatment of the clinical blood samples under a specified environment condition, so as to form a blood drying deposition film, shooting the blood drying deposition film to obtain a blood image sample; training a pre-constructed deep learning model by using the blood image sample to obtain a trained multi-task prediction model; wherein the multi-task prediction model comprises a backbone network used for extracting morphology features related to anemia, and an output layer used for executing qualitative and / or quantitative prediction tasks; and obtaining a target blood image to be screened, analyzing the target blood image based on the multi-task prediction model, and outputting a qualitative prediction result of anemia risk and / or a quantitative prediction value of anemia related indexes. The cost of anemia risk prediction can be reduced, and the accuracy of anemia prediction can be improved.

Provided are an anti-human CD117 nanobody and use thereof. The nanobody comprises at least one VHH chain. The VHH chain comprises a CDR1, a CDR2, and a CDR3. The amino acid sequence of the CDR1 is set forth in SEQ ID NO: 4, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 5, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 6; or the amino acid sequence of the CDR1 is set forth in SEQ ID NO: 7, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 8, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 9; or the amino acid sequence of the CDR1 is set forth in SEQ ID NO: 10, the amino acid sequence of the CDR2 is set forth in SEQ ID NO: 11, and the amino acid sequence of the CDR3 is set forth in SEQ ID NO: 12. The use is use of the nanobody and a formulation thereof in the preparation of a drug for treating thalassemia. The nanobody has a good binding ability to CD117, and has the advantages of small molecular weight, high binding activity, low immunogenicity, easy modification, etc.

The utility model relates to the technical field of anemia detection, and discloses a portable non-invasive anemia detection device which comprises a device body, a damping rotating shaft is installed on one side of the device body, a connecting block is rotatably connected to the interior of the damping rotating shaft, an adjustable wrist cotton sleeve is fixedly connected to one side of the connecting block, and the adjustable wrist cotton sleeve is fixedly connected to the other side of the connecting block. According to the portable non-invasive anemia detection device, the device body and the five-finger fingerstall are arranged in a matched mode, when the portable non-invasive anemia detection device is used, the device body and the five-finger fingerstall are combined to form a hand shape, compared with a conventional nested device, the portable non-invasive anemia detection device is better used in an attached mode, the five-finger fingerstall is made of light-proof soft materials, and therefore the portable non-invasive anemia detection device is convenient to use. The use comfort is improved, meanwhile, the interior is lightproof, the detection influence is reduced, and therefore the effects of being convenient to carry and improving the use comfort are achieved.

The invention particularly relates to a blood sampling device for anemia patients, and belongs to the technical field of sample storage equipment. The blood sampling device for the anemia patient comprises a storage chamber and a storage part. The storage chamber is provided with an inlet and an outlet. The storage component is contained in the storage chamber and comprises a storage disc and a plurality of limiting rings, the storage disc is rotationally connected to the storage chamber, the multiple limiting rings are arranged on the storage disc at intervals in the circumferential direction of the storage disc, each limiting ring is of a circular ring shape with a notch and comprises a rigid ring section and two flexible ring sections, the rigid ring sections are connected to the storage disc, and the flexible ring sections are connected to the storage disc. The two flexible ring sections are connected to the two sides of the rigid ring section. The storage chamber is used for providing an environment suitable for storing the blood samples, for example, a temperature adjusting device can be arranged in the storage chamber to adjust the temperature in the storage chamber, and the risk that the blood samples go bad is reduced.

Enhancing fetal hemoglobin (HbF) production through targeted promoter editing using base editing technologies. An embodiment includes a composition for enhancing fetal hemoglobin (HbF) expression in mammalian cells, the composition comprising a base editing system comprising at least two guide RNAs comprising targeting sequences selected from SEQ ID NO: 1 to SEQ ID NO: 5. Specifically, it involves the design and use of single guide RNAs (sgRNAs) targeting key regulatory elements within the gamma-globin (HBG1 / 2) promoter. The method combines the use of adenosine base editors to introduce mutations, creating new binding sites for transcriptional activators like TAL1 and KLF1, and disrupting repressor binding sites such as BCL11A and ZBTB7A / LRF. This dual-targeting approach significantly increases HbF expression, offering a potential therapeutic strategy for treating beta-hemoglobinopathies like sickle cell disease and beta-thalassemia.

A crystal form of a quinolinone compound and a use thereof further relating to a pharmaceutical composition including the crystal form, and a use of the crystal form or the pharmaceutical composition in the preparation of a drug for the treatment and prevention of HIF-related and / or EPO-related diseases (such as anemia).

The present application belongs to the field of bioinformatics, and particularly relates to a method and device for detecting a thalassemia patient's copy number variation type, the method comprising the following steps: constructing a thalassemia copy number variation database, constructing a thalassemia-related gene copy number baseline database of a healthy population, using a region range of a copy number change of a to-be-tested sample and the copy number of the region, and combining the self-constructed thalassemia copy number variation database to determine a thalassemia copy number variation type to which the sample belongs; the present application can clearly detect a known structural variation carried by a sample and related to thalassemia, and can accurately find out an atypical thalassemia-related genomic structural variation; it has been verified that the method can be used for detecting known thalassemia copy number variation types and discovering new thalassemia copy number variation types according to a standard.

The embodiment of the invention provides a construction method of a thalassemia screening model, equipment, a medium and a program product, and relates to the technical field of medical artificial intelligence. The method comprises the following steps: acquiring a whole blood cell counting parameter and a classification label of a training set sample; the training set samples are divided into minority class samples and majority class samples according to the types of the classification labels; calculating k neighbors of each minority class sample, and dividing the minority class samples into dangerous samples and non-dangerous samples according to the proportion of majority class samples in the neighbors; selecting any sample from m nearest minority-class neighbors of each dangerous sample as a neighbor sample to be tested, and generating a new sample on a connecting line of the single dangerous sample and the neighbor sample to be tested through linear interpolation; and training the parameters of the new samples, the majority samples and the non-dangerous samples to obtain a screening model. According to the application, a robust multi-class screening model is established by using conventional whole blood cell count data so as to accurately distinguish key thalassemia genotypes.

The application belongs to the field of biological medicine, discloses a HIF prolyl hydroxylase 2 inhibitor as shown in formula (I), relates to a 4-quinazolinone compound and a preparation method thereof, further relates to a pharmaceutical composition containing the compound and purposes. The HIF prolyl hydroxylase mediated disease in the application is selected from the group of uses in anemia secondary to or associated with chronic kidney disease, anemia associated with or caused by chemotherapy or anemia associated with AIDS.

A problem is to provide a composition for use in treatment and / or prevention of a complication of chronic kidney disease, an inhibitor of progression of renal damage, an inhibitor of progression of sarcopenia and an inhibitor of progression of anemia. The problem can be solved with a composition for use in treatment and / or prevention of a complication of chronic kidney disease containing lactoferrin as an active ingredient.

Provided herein, in particular, are a conjugate comprising a protein (e.g., an antibody) that specifically binds to a transferrin receptor (TFR) (e.g., human TFR (hTFR) (e.g., hTFR1)), wherein the conjugate comprises (b) a conjugate operably linked to at least one oligonucleotide that modulates the expression and / or activity of a target gene, target nucleic acid (e.g., mRNA) and / or target protein expressed by the target cell, as well as a method for producing the conjugate and a pharmaceutical composition comprising the conjugate. Furthermore, provided herein are methods of using the conjugate, including, for example, a method for treating hemoglobin disorders (e.g., sickle cell disease (SCD)) or thalassemia (e.g., α-thalassemia, β-thalassemia, δ-thalassemia, or γ-thalassemia).

The clinical history of β-hemoglobinopathies shows that the severity is mitigated by the reduction of α-globin expression, resulting from co-inheritance of α-thalassemia. The inventors identified several mutations (T>C or A>G) that can disrupt binding motifs of transcription factors using CBE- and ABE-mediated base-editing approaches. In particular, the inventors designed gRNAs that, when combined with CBEs or ABEs, disrupt binding sites for transcriptional activators (GATA1 and NF-E2) in the MCS-R2 and recapitulate the beneficial α-globin reduction observed in patients presenting both β-hemoglobinopathies and α-thalassemia. Accordingly, the present invention relates to base editing approaches for the treatment of β-hemoglobinopathies.